TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironmentArticle available on The Journal for ImmunoTherapy of Cancer (JITC)